Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 246
Filter
1.
Wien Med Wochenschr ; 152(17-18): 481-2, 2002.
Article in English | MEDLINE | ID: mdl-12385075

ABSTRACT

A 36-year-old woman developed a lung abscess following an episode of influenza. Repeated blood cultures were negative. In necrotic material obtained by bronchoscopy no pathogenic micro-organisms were found. Penicillin-clavulanate, cefodizim and metronidazole were without success. The combination therapy with imipenem-cilastatin together with clindamycin improved clinical symptoms, normalized pathological laboratory parameters and completely resolved the lung cavity.


Subject(s)
Drug Therapy, Combination/therapeutic use , Lung Abscess/drug therapy , Adult , Arthritis, Reactive/drug therapy , Cilastatin/administration & dosage , Cilastatin, Imipenem Drug Combination , Clindamycin/administration & dosage , Diagnosis, Differential , Drug Combinations , Female , Humans , Imipenem/administration & dosage , Infusions, Intravenous , Lung Abscess/diagnostic imaging , Lung Abscess/etiology , Tomography, X-Ray Computed , Treatment Outcome
2.
Wien Med Wochenschr ; 151(13-14): 288-90, 2001.
Article in English | MEDLINE | ID: mdl-11582991

ABSTRACT

We report the rare case of a recurrent hyperparathyroidism after total parathyreoidectomy due to multiple ectopic glands in a patient on long-term haemodialysis. In a today 47 years old man with membranoproliferative glomerulonephritis intermittent haemodialysis therapy was started in 1975. In 1982 an advanced secondary hyperparathyroidism with a parathormone (PTH) level > 500 pg/l was diagnosed; later on PTH concentration increased to 2,550 pg/ml. In 1987 total parathyroidectomy with parathyroid autograft into the left forearm was performed. After parathyroidectomy the PTH level fell to 150 pg/ml. In 1993 PTH concentration increased again to 1,750 pg/ml. There was no evidence for recurrent parathyroid glands in the neck or forearm. Therefore, we investigated the substernal region by 99mTc-tetrofosmin scintigraphy and magnetic resonance imaging. Both investigations showed evidence for two ectopic parathyroid glands in the anterior mediastinum. In June 1999 in an open thoracic surgical procedure only the greater parathyroid gland in the anterior mediastinum was isolated, but a second gland was detected in the posterior mediastinum. Both parathyroid glands were resected (histologically hyperplastic parathyroid gland tissue). After surgery the PTH level decreased to 340 pg/ml, but later on PTH increased again to > 1,000 pg/ml in January 2001. A control 99mTc-tetrofosmin scan showed evidence for a third ectopic parathyroid gland in the anterior mediastinum. Recurrent secondary hyperparathyroidism can rarely be caused by recurrent ectopic parathyroid glands in the mediastinum.


Subject(s)
Choristoma/diagnosis , Hyperparathyroidism, Secondary/diagnosis , Mediastinal Diseases/diagnosis , Parathyroid Glands , Parathyroidectomy , Postoperative Complications/diagnosis , Renal Dialysis , Choristoma/surgery , Humans , Hyperparathyroidism, Secondary/surgery , Magnetic Resonance Imaging , Male , Mediastinal Diseases/surgery , Middle Aged , Organophosphorus Compounds , Organotechnetium Compounds , Recurrence , Reoperation , Thoracotomy
3.
Ren Fail ; 22(5): 573-80, 2000.
Article in English | MEDLINE | ID: mdl-11041289

ABSTRACT

The objective of the study was to evaluate differences in the perinatal complications and in the 3-year follow up of infants of diabetic mothers with and without diabetic nephropathy stage IV. We compared the fetal and maternal complications and the early postpartal development until 3 years after delivery in 10 children of nephropathic diabetic mothers and 30 children of diabetic mothers without nephropathy. The mean (+/-SD) birthweight of the infants of nephropathic women was 2,250 +/- 496 g versus 3,544 +/- 435 g in the women without nephoropathy (p < 0.01). Births were premature in six pregnancies (60%) of the nephrotic women but in none of the women without nephropathy (p < 0.01). Three infants (30%) of the women with nephropathy showed respiratory distress syndrome in contrast to two babies (6%) of the women without nephropathy. Pre-eclampsia or eclampsia occurred in 6 (60%) pregnant women with and in two women (6%) without diabetic nephropathy (p < 0.01). Nephrotic syndrome was observed in 7 nephrotic women (70%) in contrast to none women without nephropathy. Three years postpartum, six of the children (60%) of nephropathic women had a body weight < the 50th percentile but none of the children of the women without nephropathy did so (p < 0.01). In addition, the children of nephropathic mothers started to speak significantly later (15 +/- 3 versus 12 +/- 13 months postpartum, p < 0.05) and had infectious diseases more commonly (60% versus 6%, p < 0.01) than the children of women without nephropathy. It can be concluded that in pregnancies of diabetic women the birth weights of the infants are significantly smaller and the fetal as well as maternal complication-rates significantly higher than in those of women without nephropathy. Also 3 years after delivery, the body weight of the children of nephropathic diabetic women is significantly lower than that of children of diabetic women without nephropathy. Additionally, children of nephropathic women are retarded in terms of linguistic development and their resistance to infections is reduced.


Subject(s)
Diabetic Nephropathies , Growth , Pregnancy in Diabetics , Adult , Body Height , Body Weight , Child, Preschool , Female , Follow-Up Studies , Humans , Infant , Infant, Newborn , Infections/etiology , Language Development , Nephrotic Syndrome/etiology , Pregnancy , Respiratory Distress Syndrome, Newborn/etiology
4.
Diabetologia ; 43(2): 231-4, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10753046

ABSTRACT

AIMS/HYPOTHESIS: The aim of the study was to examine the effect of pancreas-kidney transplantation on the progression of macrovascular diseases in Type I diabetic patients with end-stage renal disease. METHODS: The progression of cerebrovascular disease, coronary heart disease and peripheral vascular disease in uraemic patients with Type I (insulin-dependent) diabetes mellitus and who had had simultaneous pancreas-kidney transplantation was compared with that of recipients of a kidney transplant alone. Between 1986 and 1998 a total of 11 uraemic diabetic patients received a simultaneous pancreas-kidney transplantation and 10 diabetic patients a kidney transplant alone. All transplants functioned for at least 24 months, the mean observation period was 69 +/- 37 compared with 70 +/- 33 months in both patient groups. Macroangiopathic diseases were classified in four stages as described earlier. RESULTS: In the group with simultaneous pancreas-kidney transplantation progression of cerebrovascular and coronary heart disease was observed in four patients (36%) and progression of peripheral vascular disease in five subjects (45%). In the cohort with kidney transplant alone four patients (40%) showed progression of cerebrovascular and coronary heart disease and five progression of peripheral vascular disease (50%); the difference is not significant. Mean values of HbA1c (5.8 +/- 0.2 vs 7.5 +/- 0.6%, p < 0.001) and serum triglycerides (1.2 +/- 0.4 vs 2.0 +/- 1.0 mmol/l, p < 0.05) were significantly lower in the patients with pancreas-kidney transplantation than in the patient group with kidney transplant alone. Serum cholesterol concentrations and blood pressures were similar in both cohorts. CONCLUSION/INTERPRETATION: From our results we concluded that pancreas-kidney transplantation reduces risk factors for the development of macroangiopathy but fails to halt progression of macrovascular diseases similar to Type I diabetic patients with kidney transplant alone.


Subject(s)
Diabetes Mellitus, Type 1/surgery , Diabetic Angiopathies/physiopathology , Diabetic Nephropathies/surgery , Kidney Failure, Chronic/surgery , Kidney Transplantation/physiology , Pancreas Transplantation/physiology , Adult , Diabetes Mellitus, Type 1/physiopathology , Diabetic Nephropathies/physiopathology , Disease Progression , Female , Glomerular Filtration Rate , Humans , Kidney Failure, Chronic/etiology , Kidney Failure, Chronic/physiopathology , Lipids/blood , Male , Smoking
5.
Nephrol Dial Transplant ; 14(3): 655-8, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10193815

ABSTRACT

BACKGROUND: Type 2 diabetic patients with end-stage renal disease are often overweight (BMI > 24) at the start of dialysis therapy. However, there are very few reports in the literature concerning the nutritional status of these patients after prolonged haemodialysis treatment. Therefore, we compared nutritional parameters in type 2 diabetic patients and age-matched non-diabetic patients after at least 18 months of renal replacement therapy with haemodialysis. METHODS: In a cross-sectional study, we measured BMI, serum albumin, total protein, serum cholesterol and interdialytic weight gain (IWG), and performed a subjective global assessment (SGA) in 14 patients with type 2 diabetes and 16 non-diabetic patients (aged > or = 50 years, haemodialysis therapy > or = 18 months). Protein intake was estimated using the protein catabolic rate (PCR) and Kt/V was calculated to compare the dose of dialysis. RESULTS: BMI was significantly higher in patients with type 2 diabetes (30+/-7 vs 24+/-3, P<0.01). In contrast, the concentration of serum albumin was significantly lower (3180+/-499 mg/dl vs 3576+/-431 mg/dl, P<0.05), but six of the diabetic patients had signs of chronic inflammation. All other nutritional parameters did not differ between the two groups. In addition, there were no significant differences in the intake of protein (PCR 0.93+/-0.19 vs 0.92+/-0.22) and the dose of dialysis (Kt/V 1.13+/-0.19 vs 1.2+/-0.2). CONCLUSION: After > or = 18 months of haemodialysis therapy, the majority of type 2 diabetic patients (9/14) were still overweight (BMI > 24). The nutritional status of diabetic patients was similar to that of age-matched non-diabetic patients on prolonged haemodialysis, but serum albumin levels were significantly lower in diabetics. The lower albumin levels in the diabetic patients may be explained by a state of subclinical chronic inflammation.


Subject(s)
Diabetes Mellitus, Type 2/metabolism , Diabetic Nephropathies/metabolism , Nutritional Status , Renal Dialysis , Aged , Body Mass Index , Cross-Sectional Studies , Diabetes Mellitus, Type 2/complications , Diabetic Nephropathies/therapy , Female , Humans , Male , Middle Aged , Nutrition Disorders/epidemiology , Serum Albumin/analysis
6.
J Nephrol ; 12(1): 41-6, 1999.
Article in English | MEDLINE | ID: mdl-10203003

ABSTRACT

Pregnancy in type 1 diabetic women with overt nephropathy can lead to a further deterioration in renal function but it is not clear at what level of pre-conceptional GFR the risk for worsening of renal function begins to increase. Therefore we investigated the influence of pregnancy on renal function in 12 women (14 pregnancies) with pre-conceptional macroproteinuria and near-normal creatinine clearance (range 37-93 ml/min/1.73m2). S-creatinine, creatinine clearance (CrCL), HbA1c and blood pressure (BP) were measured before conception, during each trimester (12th and 24th week of gestation and last week before delivery) and three and six months post-partum. In five diabetic women with six pregnancies (group A) there was a physiological increase in CrCl of 36% up until the 24th week of gestation; their pre-conceptional mean CrCl was 80 (range 70-93) ml/min/1.73m2. In seven women with eight pregnancies (group B) CrCl decreased by 16% during the first two trimesters; the mean CrCl before conception was 61 (37-73) ml/min/1.73m2. In the last week before delivery CrCl worsened transiently in three cases in group A and four in group B, due to pre-eclampsia. Three months post-partum the mean CrCl in group A was 78 (70-91) ml/min/1.73m2, approximately the same as before pregnancy. In group B the mean CrCl was 39 (22-68) ml/min/1.73m2 at this same time; this was 36% lower than the pre-conceptional clearance. Mean HbA1c in both groups were approximately the same, but mean BP tended to be higher during pregnancy in group B, especially in the week before delivery (p<0.05). We conclude that in a high percentage of nephropathic diabetic women with significantly low CrCl before conception, renal function worsens during and after pregnancy. Inadequate antihypertensive therapy may contribute to this.


Subject(s)
Diabetes Mellitus, Type 1/physiopathology , Diabetic Nephropathies/physiopathology , Kidney/physiopathology , Pregnancy in Diabetics/physiopathology , Adult , Blood Pressure/physiology , Case-Control Studies , Creatinine/metabolism , Female , Glomerular Filtration Rate , Humans , Pregnancy , Risk Factors
7.
Am J Hypertens ; 11(11 Pt 1): 1364-70, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9832181

ABSTRACT

Bilateral nephrectomy for treatment of refractory hypertension in chronic hemodialyzed patients has been infrequently carried out. We analyzed the benefits of this operation on blood pressure, clinical state, drug treatment, and quality of life. In 10 hemodialyzed patients with refractory hypertension, systolic (SBP) and diastolic (DBP) blood pressure were measured 1 month before nephrectomy bilateral and 3, 6, 9, and 12 months after. In addition, the use of antihypertensive drugs before and after surgery was evaluated. Four patients had SBP and DBP values characteristic of malignant hypertension. In all 10 patients hypertension responded neither to reduction of plasma volume by ultrafiltration nor to multiple antihypertensive drug therapy. Hypertensive crises were associated with cerebral hemorrhage in two patients, severe encephalopathy with persistent neural dysfunction in one patient, and encephalopathy and diplopia in another. Three months after bilateral nephrectomy blood pressure decreased significantly (P < .005) and was normal in nine patients. In one noncompliant patient with intradialytic body weight increases of nearly 10%, blood pressure was still elevated. Malignant or drug-resistant hypertension with hypertensive crises is an indication for bilateral nephrectomy. The clinical state and quality of life improved in all patients in the present study and antihypertensive treatment is no longer necessary.


Subject(s)
Hypertension/surgery , Nephrectomy , Renal Dialysis , Adult , Antihypertensive Agents/therapeutic use , Blood Pressure , Female , Humans , Hypertension/drug therapy , Male , Middle Aged
8.
Clin Nephrol ; 48(3): 146-50, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9342485

ABSTRACT

Cigarette smoking was known to promote the progression of diabetic nephropathy in patients with type 1 diabetes, but its influence on the course of diabetic nephropathy in patients with type 2 diabetes had not been previously established. In a prospective follow-up study we therefore compared the progression of nephropathy in type 2 diabetic patients with or without tobacco consumption. Initiation of dialysis treatment or death of the patient were the end points of the study. 36 patients with type 2 diabetes complicated with diabetic nephropathy were included in the study, 16 smoked and 20 did not. The main outcome measures were proteinuria, arterial blood pressure, HbAlc, serum-creatinine and creatinine clearance, which were controlled at least every six months. In the smoking diabetic patients the mean (SD) creatinine-clearance decreased from 82 +/- 10 to 10 +/- 6 ml/min/1.73 m2 over a period of 62 +/- 21 months. The rate of decline of the creatinine-clearance was 1.24 +/- 0.34 ml/min/month. In the non-smoking patients the creatinine-clearance decreased from 79 +/- 8 to 9 +/- 3 ml/min/1.73 m2 within 79 +/- 27 months. The rate of decline in the creatinine-clearance was 0.99 +/- 0.35 ml/min/month (p < 0.025). HbAlc, systolic and diastolic blood pressure as well as serum cholesterol and triglycerides were not significantly different in both patient groups. Therefore, we conclude that cigarette smoking promotes the progression of diabetic nephropathy in patients with type 2 diabetes, just as it is known in type 1 diabetic patients.


Subject(s)
Diabetes Mellitus, Type 2/complications , Diabetic Nephropathies/epidemiology , Smoking/adverse effects , Case-Control Studies , Creatinine/blood , Diabetic Angiopathies/epidemiology , Diabetic Nephropathies/diagnosis , Diabetic Retinopathy/epidemiology , Disease Progression , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prospective Studies , Smoking/epidemiology , Survival Rate
9.
Ann Otol Rhinol Laryngol ; 106(5): 391-3, 1997 May.
Article in English | MEDLINE | ID: mdl-9153103

ABSTRACT

Hearing loss is a common finding in patients with end-stage renal failure. Uremic toxins, ototoxins, and axonal uremic neuropathy appear to be likely pathogenic factors. We analyzed whether an improvement in hearing capacity can be achieved with an improvement of anemia by erythropoietin (EPO) administration. Fifty patients on long-term hemodialysis in a single center were examined audiologically by otoscopy, tympanometry, pure tone audiometry, and the short increment sensitivity index. Twenty-five patients were treated with EPO in a dose of 120 U/kg per week over a period of 5 to 8 months, and the remaining 25 patients were not treated with EPO (controls). Both groups were reexamined audiologically after the study period, and the results were compared. In the group treated with EPO, the hemoglobin level increased from 7 +/- 0.9 to 11 +/- 0.8 g/dL, as against the control group, whose hemoglobin increased from 7.1 +/- 0.9 to 8 +/- g/dL. The audiologic tests were repeated at the end of the study period, and a significant improvement of hearing was found in the patients treated with EPO as compared with the control group (p < .001). Our study suggests that improvement of anemia in patients on long-term hemodialysis by administration of EPO is associated with an improvement in hearing capacity in a significant number of patients. Thus, anemia seems to be an important factor responsible for hearing disorders in patients with end-stage renal failure. Studies with larger numbers of patients are required to confirm this observation.


Subject(s)
Anemia/complications , Anemia/drug therapy , Deafness/etiology , Erythropoietin/therapeutic use , Kidney Failure, Chronic/complications , Uremia/complications , Erythropoietin/administration & dosage , Humans
11.
Ren Fail ; 19(1): 69-75, 1997 Jan.
Article in English | MEDLINE | ID: mdl-9044453

ABSTRACT

Two hundred eleven patients with acute ischemic stroke, stage III or IV, received daily intravenous infusion of 500-1000 mL low-molecular dextran (dextran 40) over a period of 4 days. In 10 cases (4.7%) acute renal failure, associated with dextran infusion, could be observed; oligoanuria occurred after a mean time of 4 (3-6) days. The incidence of dextran-induced acute renal failure was significantly higher in patients with a preexisting reduction of glomerular filtration rate below 30 mL/min/1.73 m2 (p < 0.005). Five of the patients (50%) with acute renal failure died within 4-12 days after the hemodilution therapy with dextran 40; this high lethality was due to nonrenal complications.


Subject(s)
Acute Kidney Injury/chemically induced , Anticoagulants/adverse effects , Anuria/chemically induced , Brain Ischemia/drug therapy , Dextrans/adverse effects , Acute Disease , Acute Kidney Injury/physiopathology , Adult , Aged , Aged, 80 and over , Anticoagulants/administration & dosage , Anticoagulants/therapeutic use , Anuria/physiopathology , Brain Ischemia/complications , Brain Ischemia/diagnostic imaging , Dextrans/administration & dosage , Dextrans/therapeutic use , Female , Follow-Up Studies , Glomerular Filtration Rate , Humans , Incidence , Infusions, Intravenous , Male , Middle Aged , Radiography , Renal Replacement Therapy , Retrospective Studies
12.
Wien Med Wochenschr ; 147(3): 63-6, 1997.
Article in German | MEDLINE | ID: mdl-9173675

ABSTRACT

Cerebrolysin is a peptide solution with free amino acids and biologically active peptides showing neurotrophic efficiency. In a placebo-controlled longitudinal study we investigated the effect of that drug for treatment of painful diabetic neuropathy in 20 type-II diabetic patients (9 women, 11 men, mean age 63 +/- 9 years, duration of diabetes 14 +/- 7 years). Patients received daily a cerebrolysin-infusion (20 ml in 500 ml Ringer) over a period of 10 days. In an age- and diabetes-duration matched placebo group of 10 type-II diabetic patients (7 women, 3 men, age 66 +/- 9 years, duration of diabetes 12 +/- 5 years) vitamin B infusion was administered (5 ml vitamin B complex in 500 ml Ringer) during 10 days. We compared a five-item symptom score scale (FIS) for pain, dysesthesia, paresthesia, nightly exacerbation, and sleep disturbances (grade 0 to 3) and a graphic visual analogue rating scale (VAS) for recording the magnitude of the pains (scale 0 to 100 mm) at the beginning and the end of the infusion therapy as well as 6 weeks later. Cerebrolysin was associated with a significant decrease in total FIS score from 8.7 +/- 1.9 at the start of therapy to 5.1 +/- 2.2 after 6 weeks (p < 0.001), and to a reduction of the VAS score from 4.2 +/- 0.8 to 2.8 +/- 0.9 (p < 0.001) during the same period of observation. In contrast in the placebo group the total FIS score decreased only from 7.9 +/- 1.2 at the beginning to 6.6 +/- 1.1 (p < 0.05) 6 weeks later and the VAS score from 4.5 +/- 0.6 to 4.0 +/- 0.5 (NS). Thus cerebrolysin led to a significant subjective improvement of painful diabetic neuropathy in type-II diabetic patients at least for a period of 6 weeks.


Subject(s)
Amino Acids/administration & dosage , Diabetes Mellitus, Type 2/therapy , Diabetic Neuropathies/therapy , Nootropic Agents/administration & dosage , Aged , Amino Acids/adverse effects , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Humans , Infusions, Intravenous , Longitudinal Studies , Male , Middle Aged , Neurologic Examination/drug effects , Nootropic Agents/adverse effects , Pain Measurement
13.
Clin Nephrol ; 48(6): 337-40, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9438090

ABSTRACT

Hypertension is frequently observed in end-stage renal failure. We analysed the incidence and severity of hypertension as well as antihypertensive treatment in a large group of patients on renal replacement therapy (RRT). Questionnaires were sent to all 49 dialysis centers caring for a total of 2090 patients on RRT in Austria. Hypertension was classified as mild, moderate or severe according to WHO criteria. 22 dialysis centers returned completed questionnaires accounting for 1087 patients on RRT. Of these 653 (60%) patients were hypertensive; 425 (39%) patients had mild or moderate, while 228 (21%) patients had severe hypertension. Patients with mild or moderate hypertension need on average 1.5, while those with severe hypertension on average 3.3 antihypertensive drugs. Calcium antagonists were the antihypertensive drugs most frequently administered, in 71% of the patients, followed by ACE inhibitors, alpha- and beta-blockers. Despite multidrug antihypertensive therapy severe hypertension is still a serious problem in patients on RRT. Tassin's center experience showed that longer dialysis time normalizes hypertension and reduces the requirement of antihypertensive treatment in patients on hemodialysis.


Subject(s)
Antihypertensive Agents/therapeutic use , Hypertension/drug therapy , Kidney Failure, Chronic/complications , Peritoneal Dialysis, Continuous Ambulatory , Renal Dialysis , Adult , Aged , Aged, 80 and over , Antihypertensive Agents/administration & dosage , Female , Humans , Hypertension/etiology , Male , Middle Aged , Surveys and Questionnaires
15.
Wien Klin Wochenschr ; 108(24): 781-7, 1996 Dec 27.
Article in English | MEDLINE | ID: mdl-9017890

ABSTRACT

Silicone breast implants have been surgical routine for over 30 years. An association between silicone augmentation and immune related diseases has been reported in approximately 100 cases. In a retrospective single center study we investigated 36 non-selected women with silicone breast implants and 36 sex- and age-matched controls. Autoimmune reactions were evaluated by measuring antinuclear antibodies (ANA), rheumatoid factor (RF) and thyroid gland antibodies (TMS), along with angiotensin-converting enzyme (ACE), C-reactive protein (CRP) and other immunological and laboratory parameters. In the controls only 3 (8%) women had an elevated ANA titer and 1 demonstrated thyroid autoantibodies (microsomal), giving a total of 4 (11%) women with detectable autoantibodies. By contrast, 12 (33%) of the 36 women with silicone augmentation had raised ANA titers (> or = 1 : 80), a significantly higher percentage than in the control group (p < 0.02). Of the 12 women, 1 showed antismooth muscle antibodies (ASMA; titer 1 : 40) and 2 of the patients displayed antineutrophilic cytoplasm antibodies (ANCA; 1 : 320 and 1 : 40, respectively), one of the latter also being positive for rheumatoid factor. 2 further women demonstrated thyroid autoantibodies (microsomal), giving a total of 14 (39%) women in whom significant autoantibodies were detectable. Clinical symptoms (musculoskeletal) were present in 1 patient. Most of the observed autoantibodies were organ-unspecific, with a predominance of elevated ANA titers of the heterogeneous type and not related to a distinct clinical entity. However, none of the investigated women with silicone breast implants showed clinical symptoms or signs of connective tissue disease according to ARA criteria.


Subject(s)
Autoimmune Diseases/chemically induced , Breast Implants , Mammaplasty , Silicones/adverse effects , Acute-Phase Proteins/metabolism , Adult , Aged , Aged, 80 and over , Austria , Autoantibodies/blood , Autoimmune Diseases/immunology , Female , Humans , Middle Aged , Organ Specificity/immunology , Retrospective Studies , Risk Factors
17.
Diabetes Care ; 19(6): 625-8, 1996 Jun.
Article in English | MEDLINE | ID: mdl-8725862

ABSTRACT

OBJECTIVE: To study the influence of cigarette smoking on the survival rate of diabetic patients on hemodialysis. RESEARCH DESIGN AND METHODS: We evaluated 1- and 5-year survival rates and the mean values of HbA1c, serum lipids, fibrinogen, and blood pressure. We compared the prevalence of vascular damage at the beginning of dialysis therapy and the endpoint of the study, as well as the causes of death in 22 diabetic patients who smoked (> 10 cigarettes/day) and 30 nonsmoking diabetic patients. RESULTS: There were no differences with respect to HbA1c, cholesterol, and triglycerides. In contrast, diabetic patients with tobacco consumption had significantly (P < 0.05) higher levels of fibrinogen (428 +/- 98 vs. 378 +/- 76 mg/dl) and higher systolic blood pressures (154 +/- 12 vs. 146 +/- 13 mm Hg) than the nonsmoking group. The 1- and 5-year survival rates of the smoking patients were 68 and 9%, respectively, and in the nonsmoking subjects, 80 and 37%, respectively (P < 0.05). The prevalence of vascular damage was similar in both groups, but at the endpoint of the study, the incidence of myocardial infarctions was significantly higher (P < 0.005) in the smoking patients (77 vs. 13%). Cardiovascular events were the most frequent cause of death in both patient groups but more frequently in the smoking subjects (80 vs. 63%). CONCLUSIONS: Hemodialyzed diabetic cigarette smokers show higher fibrinogen and systolic blood pressure values, a higher incidence of myocardial infarctions, and their 5-year survival rate is significantly decreased when compared with nonsmoking patients on hemodialysis.


Subject(s)
Cardiovascular Diseases/epidemiology , Cerebrovascular Disorders/epidemiology , Diabetic Angiopathies/epidemiology , Diabetic Nephropathies/therapy , Kidney Failure, Chronic/therapy , Renal Dialysis/mortality , Smoking , Blood Pressure , Cardiovascular Diseases/mortality , Cerebrovascular Disorders/mortality , Cholesterol/blood , Diabetes Mellitus, Type 1/mortality , Diabetes Mellitus, Type 2/mortality , Diabetic Angiopathies/mortality , Diabetic Nephropathies/blood , Diabetic Nephropathies/mortality , Female , Fibrinogen/analysis , Glycated Hemoglobin/analysis , Humans , Kidney Failure, Chronic/mortality , Male , Middle Aged , Prevalence , Retrospective Studies , Risk Assessment , Risk Factors , Survival Rate , Time Factors , Triglycerides/blood
19.
Wien Klin Wochenschr ; 108(11): 334-7, 1996.
Article in German | MEDLINE | ID: mdl-8767987

ABSTRACT

Atraumatic rhabdomyolysis with consecutive oliguric renal failure occurred in a 67-year-old man with chronic renal insufficiency in the pre-dialysis phase after four years of therapy with lovastatin without complications. Diuresis remained low after normalization of the muscle enzymes, and the patient required chronic hemodialysis. This case report shows that lovastatin-associated rhabdomyolysis with consecutive myoglobinuric renal failure can be seen also after long-standing lovastatin therapy. In pre-existing renal insufficiency this can lead to earlier requirement of chronic dialysis treatment.


Subject(s)
Anticholesteremic Agents/adverse effects , Hypercholesterolemia/drug therapy , Kidney Failure, Chronic/chemically induced , Lovastatin/adverse effects , Myoglobinuria/chemically induced , Nephrotic Syndrome/drug therapy , Aged , Anticholesteremic Agents/administration & dosage , Humans , Kidney Function Tests , Lovastatin/administration & dosage , Male , Renal Dialysis
20.
Wien Med Wochenschr ; 146(4): 75-8, 1996.
Article in English | MEDLINE | ID: mdl-8650942

ABSTRACT

In recent studies, it has been demonstrated that strict dietary protein restriction has a beneficial effect on renal transplant patients who show chronic rejection, or transplant fibrosis respectively; however, the protein intake in those investigations usually has been below 0.6 g/kg day, and such a strong restriction may be associated with both a negative nitrogen balance, and low patient compliance. Our study was therefore undertaken to investigate whether the same beneficial effect could be attained with a more moderate dietary protein restriction in renal transplant recipients. In a randomized cross-over study, 14 patients with biopsy-proven transplant fibrosis received a mildly protein restricted diet (0.7 g/kg/day), and a normal protein diet (1.2 g/kg/day) respectively during two 3-week periods. In the patients undergoing moderate protein restriction, a significant reduction in urinary albumin, and total protein excretion, as well as a decrease in albumin/creatinine ratio was observed at the end of the 3-week period when compared to the patients on normal protein diet (p < 0.05). The 51Cr-EDTA-clearance did not differ at the end of each of these dietary periods. In contrast to earlier studies with lower protein intake, the moderate protein restriction in our investigation was not associated with a decrease in serum proteins. In conclusion, a mildly restricted protein intake has also proved effective in significantly reducing the urinary protein excretion in patients with renal transplant fibrosis, yet, without causing decreasing serumprotein-concentrations, which are a sign for a negative nitrogen balance.


Subject(s)
Diet, Protein-Restricted , Graft Rejection/diet therapy , Kidney Transplantation , Postoperative Complications/diet therapy , Proteinuria/diet therapy , Adult , Albuminuria/diet therapy , Albuminuria/urine , Blood Proteins/urine , Cross-Over Studies , Female , Graft Rejection/urine , Humans , Kidney Function Tests , Kidney Transplantation/physiology , Male , Middle Aged , Postoperative Complications/urine , Proteinuria/urine
SELECTION OF CITATIONS
SEARCH DETAIL
...